Andrew Falzon

Dr. Andrew Falzon


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in Clinical Radiology
Verified
Journal Article
Closed access
PDF file
OCO. Carney
O. Carney
AFAndrew Falzon
Andrew Falzon
AMA.D. MacKinnon
A.D. MacKinnon

17 September 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JSJ. Siddiqui
J. Siddiqui
FBF. Bala
F. Bala
SSS. Sciacca
S. Sciacca
AFAndrew Falzon
Andrew Falzon
MBM. Benger
M. Benger
TBThomas C Booth
Thomas C Booth
BACKGROUND AND PURPOSE: Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction testing, but the sensitivity is limited. Carotid CTA is a routine acute stroke investigation and includes the lung apices. We evaluated CTA as a potential COVID-19 diagnostic imaging biomarker. MATERIALS AND METHODS: This was a multicenter, retrospective study (n = 225) including CTAs of patients with suspected acute stroke from 3 hyperacute stroke units (March-April 2020). We evaluated the reliability and accuracy of candidate diagnostic imaging biomarkers. Demographics, clinical features, and risk factors for COVID-19 and stroke were analyzed using univariate and multivariate statistics. RESULTS: Apical ground-glass opacification was present in 22.2% (50/225) of patients. Ground-glass opacification had high interrater reliability (Fleiss κ = 0.81; 95% CI, 0.68–0.95) and, compared with reverse-transcriptase polymerase chain reaction, had good diagnostic performance (sensitivity, 75% [95% CI, 56–87]; specificity, 81% [95% CI, 71–88]; OR = 11.65 [95% CI, 4.14–32.78]; P < .001) on multivariate analysis. In contrast, all other contemporaneous demographic, clinical, and imaging features available at CTA were not diagnostic for COVID-19. The presence of apical ground-glass opacification was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .017; hazard ratio = 3.51; 95% CI, 1.42–8.66; P = .006). CONCLUSIONS: We identified a simple, reliable, and accurate COVID-19 diagnostic and prognostic imaging biomarker obtained from CTA lung apices: the presence or absence of ground-glass opacification. Our findings have important implications in the management of patients presenting with suspected stroke through early identification of COVID-19 and the subsequent limitation of disease transmission.

24 December 2024 in Brain Sciences
Verified
Journal Article
Open access
AFAndrew Falzon
Andrew Falzon
SMShigeta Miyake
Shigeta Miyake
TKTze Phei Kee
Tze Phei Kee
HAHugo Andrade-Barazarte
Hugo Andrade-Barazarte
TKTimo Krings
Timo Krings
Background: Anterior choroidal artery (AChoA) aneurysms pose a challenge for both endovascular and clipping procedures. The eloquent territory supplied by the parent vessel has limited collateralization and its compromise can lead to significant morbidity. This study aims to analyze the clinical outcomes and procedure-related complications of clipping and endovascular treatment of AChoA aneurysms to aid physician decision making. Methods: Thirty-two ruptured and unruptured AChoA aneurysms that underwent catheter angiography at a single neurovascular center between January 2000 and December 2023 were included. Either conservative management, clipping, and/or endovascular treatment were performed. Clinical outcomes and complications were analyzed retrospectively. Results: Twenty-four endovascular treatments and seven clipping procedures were included. Of the total 24 endovascular procedures, 46% were primary coiling, 25% were balloon-assisted coiling, 13% were flow diverting stent, 8% were combined balloon-assisted coiling and flow diverting stent, and 8% were combined balloon-assisted and stent-assisted coiling. There was no procedure-related mortality in both groups. No intra- or post-procedural ruptures/re-ruptures occurred during follow-up in both endovascular and clipping cohorts. AChoA territory infarcts occurred in 4% of the endovascular and 29% of the clipping cohorts. Other thromboembolic complications occurred in 4% of the endovascular cohort. The recurrence rate requiring retreatment was 12.5% for the endovascular and 43% for the clipping cohort. A favorable clinical outcome (mRS ≤ 2) was 78% for the endovascular cohort and 67% for the clipping cohort. Conclusions: Endovascular and clipping outcomes align with prior studies, with endovascular showing a favorable safety profile. Both approaches are viable, though they present distinct risks and advantages.

29 April 2025 in Interventional Neuroradiology
Verified
Journal Article
Closed access
AFAndrew Falzon
Andrew Falzon
AAAhmed Abdelghafar
Ahmed Abdelghafar
EHEef Hendriks
Eef Hendriks
HBHugo Andrade Barazarte
Hugo Andrade Barazarte
AKAlex Kostynskyy
Alex Kostynskyy
PMPascal J. Mosimann
Pascal J. Mosimann
Background and purpose: Despite a rapidly growing body of literature supporting the treatment of chronic subdural hematoma (cSDH) with middle meningeal artery embolization (MMAE), real-life data is still scarce. This study aimed to evaluate MMAE radiological and clinical outcomes, based on radiological characteristics. Materials and Methods: Fifty-two cSDH patients, treated by MMAE as a post-CSDH evacuation therapy in a single tertiary center, were included. Radiological outcome was evaluated with cSDH thickness/volume difference at routine follow-up compared to pre-MMAE CT head imaging. The cohort was divided into groups pertaining to cSDH laterality (bilateral and unilateral cSDH) and pre-MMAE hematoma thickness (>15 mm and ≤15 mm) for analysis. Patients who underwent evacuation after MMAE were not included in the analysis to eliminate bias of surgical effect on hematoma progression. Results: Thirty patients had bilateral, and 22 patients had unilateral cSDH treated with bilateral and unilateral MMAE respectively. Twenty-nine patients had >15 mm pre-MMAE hematoma thickness, and 23 had ≤15 mm pre-MMAE hematoma thickness. Mean cSDH volume was lower at all follow-up intervals when compared to baseline and was reduced by a factor of 10 at the 3–6-month interval. The mean cSDH thickness was significantly lower at all three follow-up intervals when comparing each group (bilateral and unilateral MMAE) (pre-treatment hematoma thickness >15 mm and ≤15 mm). Larger hematomas with a thickness of >15 mm had a significantly greater reduction in mean cSDH volume interval follow-up than hematomas measuring ≤15 mm (1–3 months—63 mm 3 , 40.6–85.69, P < .001). Unilateral cSDH and MMAE demonstrated greater cSDH volume reduction compared to bilateral cSDH and MMAE at 1–3 months (42, 15.2–68.8, .001) and 3-6 months (33.7, 5.2-72.7, .043). No procedure-related major complications or deaths or recurrences were observed. Conclusions: Adjunctive MMAE after surgical evacuation appears safe and effective. MMAE is particularly effective for larger pre-treatment hematomas >15 mm (compared to ≤15 mm) and for unilateral cSDH and MMAE (compared to bilateral cSDH and MMAE).

30 October 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AAAhmed Abdelghafar
Ahmed Abdelghafar
AFAndrew Falzon
Andrew Falzon
EHEef J. Hendriks
Eef J. Hendriks
IRIvan Radovanovic
Ivan Radovanovic
HAHugo Andrade-Barazarte
Hugo Andrade-Barazarte
PMPascal J. Mosimann
Pascal J. Mosimann
Background/Objectives: MMAE (middle meningeal artery embolization) has emerged as a potential effective treatment for cSDH (chronic subdural hematoma). In this study, MMAE efficiency with regards to cSDH cause and architecture was explored. The comparability of cSDH thickness and volume as parameters for cSDH pre- and post-MMAE assessment was also analyzed. Methods: In this retrospective cohort study, 52 consecutive cSDH patients treated with MMAE in a single tertiary center were included. The cohort was divided into two group pairs pertaining to cSDH cause (spontaneous or traumatic) and cSDH architecture (non-mature or mature). The radiological outcome was compared in each group before and after MMAE and between each group pair using CT imaging. A correlation analysis between cSDH thickness and volume before and after MMAE was also performed. Results: A statistically significant positive linear association between cSDH thickness and volume at admission and at each follow-up interval (1–3, 3–6, 6–12 months) was noticed. cSDH thickness and volume reduction in each group was statistically significant, except for a traumatic cSDH volume reduction at 6–12 months. There was no statistically significant difference between each group pair in the cSDH thickness and volume reduction difference at all the follow-up intervals. Conclusions: A comparable efficiency of MMAE may be achieved in non-mature and mature as well as in spontaneous and traumatic cSDH, with an advantage for spontaneous cSDH at 6–12 months follow-up compared to traumatic cSDH. Traumatic cSDH may require a relatively long-term follow-up post-MMAE. cSDH thickness and volume, as parameters for pre- and post-MMAE cSDH evaluation, appear similar.

13 May 2025 in World Neurosurgery
Verified
Journal Article
Open access
ZIZeev Itsekson-Hayosh
Zeev Itsekson-Hayosh
AFAndrew Falzon
Andrew Falzon
HBHugo Andrade Barazarte
Hugo Andrade Barazarte
RARonit Agid
Ronit Agid
EHEef Hendriks
Eef Hendriks
TKTimo Krings
Timo Krings
Headaches following treatment of unruptured intracranial aneurysms with flow diverting stents is a known, however under-reported, entity. Prevalence of this phenomenon, its clinical and procedural correlates, as well as its clinical course and correlation to aneurysm location and size have not been reported in the past. This manuscript aims to quantify the prevalence of the phenomenon, describe its natural course, and identify risk factors for its emergence. Within our prospectively collected institutional database, we identified 141 consecutive patients treated electively for unruptured intracranial aneurysms by flow diversion between 2015 and 2021 who had a minimum of 2 years of clinical follow-up. The mean patient age was 55.7 (±13) y/o and 120/141 patients (85%) were females. Based on chart review and clinical notes we evaluated the presence of postprocedural headache complaints and correlated these with anatomical and periprocedural data. Additionally we have assessed charts of 88 patient who underwent aneurysm coiling without flow diversion during the same time period. Twenty-four (17%) patients complained of new headaches postflow diversion which were hemicranial or holocranial (n = 17) or retro-orbital (n = 7) in nature. Headaches were most common in paraclinoid, paraophthalmic, and cavernous aneurysms, while retro-orbital pain was correlated to larger aneurysms of same locations mean dimensions and older age (Pearson's correlation, 13 mm ± 5.4, P = 0.04; 65 ± 14, P = 0.048). Two stent constructs were also correlated to retro-orbital headaches (hazard ratio [HR] 3.8, P = 0.03, confidence interval [CI] 1.0-16.4). In addition, in 15 of 24 cases (62.5%) of headache presentations, the stent construct was crossing the dura. In 6 of 7 (87.5%) of patients presenting with retro-orbital headaches the stent construct was crossing the dural ring. The clinical course of the pain syndrome was invariably benign and short-lived (<1 year long). During the same time period only 3 patients (3.4%) in the elective coiling without flow diverter group presented with various duration of holocranial eventually resolving headaches. In our cohort, new postprocedural headaches following flow-diversion were present in 17% of patients thus constituting a common adverse event that was exclusively related to anterior circulation aneurysms, in contrast to only 3.4% prevalence of new postprocedural headaches following elective aneurysm coiling. The phenomenon was short-lived and benign, related to larger aneurysm size, proximity to the dural ring in the treated segment, double stent construct, and older age. We hypothesize that these headaches may be related to meningeal irritation. We recommend that patients are educated during the consent process of this phenomenon and its clinical course prior to treatment.